Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nedyalko Ivanov

Dermatology Roswell, GA Doctor of Osteopathy

NPI 1548827710 CMS profile 6072273

2500 Hospital Blvd Ste 280, Roswell, GA 30076

Open in the dashboard

General payments

$8,706

315 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nedyalko Ivanov of Roswell, GA is reported in the CMS Open Payments database as having received $8,706 across 315 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,383 41
2024 General $2,544 108
2023 General $2,112 79
2022 General $1,142 33
2021 General $1,036 41
2020 General $380 11
2019 General $108 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nedyalko Ivanov
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Nedyalko Ivanov were reported at $1,383. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Nedyalko Ivanov Dermatology median Middle half National median
2019 $108 $454 $129–$1,240 $163
2020 $380 $235 $81–$756 $114
2021 $1,036 $377 $108–$1,108 $132
2022 $1,142 $514 $143–$1,391 $149
2023 $2,112 $607 $159–$1,674 $160
2024 $2,544 $751 $204–$1,903 $164
2025 $1,383 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,229 51 payments
  2. LEO Pharma Inc. $943 43 payments
  3. Sun Pharmaceutical Industries Inc. $923 50 payments
  4. Genzyme Corporation $619 14 payments
  5. Arcutis Biotherapeutics, Inc. $562 25 payments
  6. Janssen Scientific Affairs, LLC $482 4 payments
  7. Dermavant Sciences, Inc. $475 6 payments
  8. Regeneron Healthcare Solutions, Inc. $405 12 payments
  9. Amgen Inc. $374 14 payments
  10. Janssen Biotech, Inc. $332 17 payments
  11. Other $2,363 79 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,538 313 payments
  2. Education $168 2 payments
Products named General payments · program years 2019–2025
  1. ADBRY $922 42 payments
  2. TREMFYA $814 21 payments
  3. VTAMA $748 11 payments
  4. DUPIXENT $619 14 payments
  5. SKYRIZI $590 23 payments
  6. ILUMYA $558 37 payments
  7. Zoryve $383 19 payments
  8. Otezla $374 14 payments
  9. Winlevi $365 13 payments
  10. RINVOQ $362 16 payments
  11. Other $3,004 111 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 77 billing codes

Paid by Medicare

$144,220

Medicare's payments for the services billed

Medicare patients

383

Average age 75

Services billed

1,643

169 women, 214 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 40%
Ischemic heart disease 29%
Atrial fibrillation 21%
Diabetes 20%
Chronic kidney disease 17%
Cancer 17%
Depression 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ADBRY
  • LEO Pharma Inc. $635
$635 — —
Zoryve
  • Arcutis Biotherapeutics, Inc. $363
$363 — —
DUPIXENT
  • GENZYME CORPORATION $205
  • Regeneron Healthcare Solutions, Inc. $99
$304 — —
SKYRIZI
  • AbbVie, Inc. $271
$271 — —
Otezla
  • Amgen Inc. $217
$217 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

315 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record